Current strategies for predicting side effects from second generation antipsychotics in youth

References

• Cooper WO, Arbogast PG, Ding H, et al.. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr Off J Ambul Pediatr Assoc. 2006 Apr;6(2):79–83.
   PubMedGoogle Scholar
• Carton L, Cottencin O, Lapeyre-Mestre M, et al. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic Review of recent prescription trends. Curr Pharm Des. 2015;21(23):3280–3297.
   PubMed Web of Science ®Google Scholar
• Oshikoya KA, Carroll R, Aka I, et al. Adverse events associated with risperidone use in pediatric patients: a retrospective biobank study. Drugs Real World Outcomes. 2019 6. Jun(2):59–71.
   Google Scholar
• Zito JM, Safer DJ, Sai D, et al. Psychotropic medication patterns among youth in foster care. Pediatrics. 2008 Jan;121(1):e157–163.
   PubMed Web of Science ®Google Scholar
• Glesener D, Anderson G, Li X, et al. Psychotropic medication patterns for american indian children in foster care. J Child Adolesc Psychopharmacol. 2018 Apr;28(3):225–231.
   PubMed Web of Science ®Google Scholar
• Ó H, Zoëga H, Aagaard L, et al. International trends in antipsychotic use: a study in 16 countries, 2005–2014. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2017 Oct;27(10):1064–1076.
   PubMed Web of Science ®Google Scholar
• Bushnell GA, Crystal S, Olfson M. Trends in antipsychotic medication use in young privately insured children. J Am Acad Child Adolesc Psychiatry. 2020 Oct 19.
   PubMed Web of Science ®Google Scholar
• Edelsohn GA, Karpov I, Parthasarathy M, et al. Trends in antipsychotic prescribing in medicaid-eligible youth. J Am Acad Child Adolesc Psychiatry. 2017 Jan;56(1):59–66.
   PubMed Web of Science ®Google Scholar
• Melvin KE, Hart JC, Sorvig RD. Second-generation antipsychotic prescribing patterns for pediatric patients enrolled in west virginia medicaid. Psychiatr Serv Wash DC. 2017 Oct 1;68(10):1061–1067.
   PubMed Web of Science ®Google Scholar
• Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69(Suppl 4):26–36.
   PubMed Web of Science ®Google Scholar
• Cohen D, Bonnot O, Bodeau N, et al. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol. 2012 Jun;32(3):309–316.
   PubMed Web of Science ®Google Scholar
• Hong IS, Bishop JR. Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother. 2010 Aug;44(7–8):1171–1180.
   PubMed Web of Science ®Google Scholar
• Kamin J, Manwani S, Hughes D. Emergency psychiatry: extrapyramidal side effects in the psychiatric emergency service. Psychiatr Serv Wash DC. 2000 Mar;51(3):287–289..
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2001 May;297(2):711–717.
   PubMed Web of Science ®Google Scholar
• Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2004 Jan;29(1):133–145.
   PubMed Web of Science ®Google Scholar
• Stentebjerg-Olesen M, Jeppesen P, Pagsberg AK, et al. Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics. J Child Adolesc Psychopharmacol. 2013 Dec;23(10):665–675.
   PubMed Web of Science ®Google Scholar
• Jerrell JM, Hwang T-L, Livingston TS. Neurological adverse events associated with antipsychotic treatment in children and adolescents. J Child Neurol. 2008 Dec;23(12):1392–1399.
   PubMed Web of Science ®Google Scholar
• Ivashchenko D, Buromskaya N, Savchenko L, et al. Global trigger tool in child psychiatry: treatment safety evaluation in adolescents with an acute psychotic episode. Int J Risk Saf Med. 2020;31(1):25–35.
   PubMed Web of Science ®Google Scholar
• Garcia-Amador M, Merchán-Naranjo J, Tapia C, et al. Neurological adverse effects of antipsychotics in children and adolescents. J Clin Psychopharmacol. 2015 Dec;35(6):686–693.
   PubMed Web of Science ®Google Scholar
• Kumar S, Kelly AS. Review of childhood obesity: from epidemiology, etiology, and comorbidities to clinical assessment and treatment. Mayo Clin Proc. 2017 Feb;92(2):251–265.
   PubMed Web of Science ®Google Scholar
• Stigler KA, Potenza MN, Posey DJ, et al. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr Drugs. 2004;6(1):33–44.
   PubMedGoogle Scholar
• Schoemakers RJ, Van Kesteren C, Van Rosmalen J, et al. No differences in weight gain between risperidone and aripiprazole in children and adolescents after 12 months. J Child Adolesc Psychopharmacol. 2019 Apr;29(3):192–196.
   PubMed Web of Science ®Google Scholar
• DeVane CL, Charles JM, Abramson RK, et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy. 2019 Jun;39(6):626–635.
   PubMed Web of Science ®Google Scholar
• Upadhyay N, Patel A, Chan W, et al. Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders. Psychiatry Res. 2019;276:151–159.
   PubMed Web of Science ®Google Scholar
• Provensi G, Blandina P, Passani MB. The histaminergic system as a target for the prevention of obesity and metabolic syndrome. Neuropharmacology. 2016 Jul;106:3–12.
   PubMed Web of Science ®Google Scholar
• Voigt J-P FH. Serotonin controlling feeding and satiety. Behav Brain Res. 2015 Jan;15(277):14–31.
   Google Scholar
• Nurmi EL, Spilman SL, Whelan F, et al. Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Transl Psychiatry. 2013 Jun;25(3):e274.
   Google Scholar
• Lee AK, Bishop JR. Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications. Pharmacogenomics. 2011 Jul;12(7):999–1016.
   PubMed Web of Science ®Google Scholar
• Stinson SE, Jonsson AE, Lund MAV, et al. Fasting plasma GLP-1 associates with overweight/obesity and cardiometabolic risk factors in children and adolescents. J Clin Endocrinol Metab. 2021. [Online ahead of print].
   PubMed Web of Science ®Google Scholar
• Mayfield K, Siskind D, Winckel K, et al. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. J Psychopharmacol. 2016 Mar;30(3):227–236.
   PubMed Web of Science ®Google Scholar
• Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004 Aug;24(4):429–436.
   PubMed Web of Science ®Google Scholar
• Goldstein BI, Birmaher B, Axelson DA, et al. Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry. 2008 Dec;69(12):1953–1959.
   PubMed Web of Science ®Google Scholar
• Vandenberghe F, Najar-Giroud A, Holzer L, et al. Second-generation antipsychotics in adolescent psychiatric patients: metabolic effects and impact of an early weight change to predict longer term weight gain. J Child Adolesc Psychopharmacol. 2018;28(4):258–265.
   PubMed Web of Science ®Google Scholar
• Hoekstra PJ, Troost PW, Lahuis BE, et al. Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. J Child Adolesc Psychopharmacol. 2010 Dec;20(6):473–477.
   PubMed Web of Science ®Google Scholar
• Correia CT, Almeida JP, Santos PE, et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J. 2010;Oct;10(5):418–430.
   PubMed Web of Science ®Google Scholar
• Mankoski R, Stockton G, Manos G, et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. J Child Adolesc Psychopharmacol. 2013 Oct;23(8):572–576.
   PubMed Web of Science ®Google Scholar
• Taylor JH, Jakubovski E, Gabriel D, et al. Predictors and moderators of antipsychotic-related weight gain in the treatment of early-onset schizophrenia spectrum disorders study. J Child Adolesc Psychopharmacol. 2018 Sep;28(7):474–484.
   PubMed Web of Science ®Google Scholar
• Jensen KG, Correll CU, Rudå D, et al. Cardiometabolic adverse effects and its predictors in children and adolescents with first-episode psychosis during treatment with quetiapine-extended release versus aripiprazole: 12-week results from the tolerance and effect of antipsychotics in children and adolescents with psychosis (TEA) trial. J Am Acad Child Adolesc Psychiatry. 2019 Nov;58(11):1062–1078.
   PubMed Web of Science ®Google Scholar
• Kemp DE, Correll CU, Mauricio T, et al. Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia. J Child Adolesc Psychopharmacol. 2013 Oct;23(8):522–530.
   PubMed Web of Science ®Google Scholar
• Ulloa RE, Pérez-Garza R, Arce S, et al. A prospective study of adverse effects of antipsychotics in adolescents with schizophrenia during a 6-month follow-up. Int Clin Psychopharmacol. 2019 Jan;34(1):33–36.
   PubMed Web of Science ®Google Scholar
• Panagiotopoulos C, Ronsley R, Kuzeljevic B, et al. Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with second-generation antipsychotics. Can J Psychiatry Rev Can Psychiatr. 2012 Jan;57(1):34–44.
   PubMed Web of Science ®Google Scholar
• Croteau C, Ben Amor L, Ilies D, et al. Impact of psychoactive drug use on developing obesity among children and adolescents with autism spectrum diagnosis: a nested case-control study. Child Obes Print. 2019 Mar;15(2):131–141.
   PubMed Web of Science ®Google Scholar
• Kelly DL, Conley RR, Love RC, et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol. 1998;8(3):151–159.
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999 Nov;156(11):1686–1696.
   PubMed Web of Science ®Google Scholar
• Arnaiz JA, Rodrigues-Silva C, Mezquida G, et al. The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis. Psychopharmacology (Berl). 2021 Mar;238(3):665–676.
   PubMed Web of Science ®Google Scholar
• Calarge CA, Ellingrod VL, Zimmerman B, et al. Leptin gene −2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet. 2009 Dec;19(6):320–327. Nussbaum LA, Dumitrascu V, Tudor A, Gradinaru R, Andreescu N, Puiu M. Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype. Rom J Morphol Embryol. 2014;55(3):877-884.
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry. 2012 Sep;69(9):904–912.
   PubMed Web of Science ®Google Scholar
• Zhang J-P, Lencz T, Zhang RX, et al. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull. 2016 Nov;42(6):1418–1437.
   PubMed Web of Science ®Google Scholar
• Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013 Jul-Sep;6(3):168–175.
   PubMedGoogle Scholar
• Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol Oxf Engl. 2008 Mar;22(2 Suppl):12–19.
   PubMedGoogle Scholar
• Ál M, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017;45:25–34.
   PubMed Web of Science ®Google Scholar
• Calarge CA, Ellingrod VL, Acion L, et al. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009 May;19(5):373–382.
   PubMed Web of Science ®Google Scholar
• Gopal S, Lane R, Nuamah I, et al. Evaluation of potentially prolactin-related adverse events and sexual maturation in adolescents with schizophrenia treated with paliperidone extended-release (ER) for 2 years: a post hoc analysis of an open-label multicenter study. CNS Drugs. 2017 Sep;31(9):797–808.
   PubMed Web of Science ®Google Scholar
• Roke Y, Buitelaar JK, Boot AM, et al. Risk of hyperprolactinemia and sexual side effects in males 10–20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. J Child Adolesc Psychopharmacol. 2012 Dec;22(6):432–439.
   PubMed Web of Science ®Google Scholar
• Thompson J, Thomas N, Singleton A, et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics. 1997 Dec;7(6):479–484.
   PubMedGoogle Scholar
• Jönsson EG, Nöthen MM, Grünhage F, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry. 1999 May;4(3):290–296.
   PubMed Web of Science ®Google Scholar
• Arinami T, Gao M, Hamaguchi H, et al. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet. 1997 Apr;6(4):577–582.
   PubMed Web of Science ®Google Scholar
• Pohjalainen T, Rinne JO, Någren K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry. 1998 May;3(3):256–260.
   PubMed Web of Science ®Google Scholar
• Dos Santos JA, Henriques TB, De Mello MP, et al. Hyperprolactinemia in children and adolescents with use of risperidone: clinical and molecular genetics aspects. J Child Adolesc Psychopharmacol. 2015 Dec;25(10):738–748.
   PubMed Web of Science ®Google Scholar
• Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007 Feb 15;61(4):545–550.
   PubMed Web of Science ®Google Scholar
• Dwyer JB, Leslie FM. Adolescent maturation of dopamine D1 and D2 receptor function and interactions in rodents. PloS One. 2016;11(1):e0146966.
   PubMed Web of Science ®Google Scholar
• Abilify [Package Insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc; 2014.
   Google Scholar
• Seroquel [Package Insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2016.
   Google Scholar
• Zhang L, Brown SJ, Shan Y, et al. CYP2D6 genetic polymorphisms and risperidone pharmacokinetics: a systematic review and meta-analysis. Pharmacotherapy. 2020 Jul;40(7):632–647.
   PubMed Web of Science ®Google Scholar
• Maruf AA, Stein K, Arnold PD, et al. CYP2D6 and antipsychotic treatment outcomes in children and youth: a systematic review. J Child Adolesc Psychopharmacol. 2020 Oct Feb;31(1):33-45.
   PubMed Web of Science ®Google Scholar
• Milosavljevic F, Bukvic N, Pavlovic Z, et al. Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis. JAMA Psychiatry. 2020 NovMar 1;78(3):270-280.
   Web of Science ®Google Scholar
• Dodsworth T, Kim DD, Procyshyn RM, et al. A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents. Child Adolesc Psychiatry Ment Health. 2018;12:37.
   PubMed Web of Science ®Google Scholar
• Oshikoya KA, Neely KM, Carroll RJ, et al. CYP2D6 genotype and adverse events to risperidone in children and adolescents. Pediatr Res. 2019;85(5):602–606.
   PubMed Web of Science ®Google Scholar
• Jallaq SA, Verba M, Strawn JR, et al. CYP2D6 phenotype influences aripiprazole tolerability in pediatric patients with mood disorders. J Child Adolesc Psychopharmacol. 2020 Aug 1 Feb;31(1):56-62.
   PubMed Web of Science ®Google Scholar
• Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009 Oct 28;302(16):1765–1773.
   PubMed Web of Science ®Google Scholar
• Al-Dhaher Z, Kapoor S, Saito E, et al. Activating and tranquilizing effects of first-time treatment with aripiprazole, olanzapine, quetiapine, and risperidone in youth. J Child Adolesc Psychopharmacol. 2016;26(5):458–470.
   PubMed Web of Science ®Google Scholar
• Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry. 2008 Jul;69(7):1157–1165.
   PubMed Web of Science ®Google Scholar
• Neuhut R, Lindenmayer J-P SR. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):415–422.
   PubMed Web of Science ®Google Scholar
• Kato D, Kawanishi C, Kishida I, et al. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol. 2007 Nov;63(11):991–996.
   PubMed Web of Science ®Google Scholar
• Risperdal [Package Insert]. Wallingstown, Little Island, County Cork, Ireland: Janssen Pharmaceutical Ltd; 2009.
   Google Scholar
• Coustals N, Ménard M-L CD. Aripiprazole in children and adolescents. J Child Adolesc Psychopharmacol. 2020 Sep1 Feb;31(1);4-32.
   PubMedGoogle Scholar
• Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
   Google Scholar
• Reichelt AC. Adolescent maturational transitions in the prefrontal cortex and dopamine signaling as a risk factor for the development of obesity and high fat/high sugar diet induced cognitive deficits. Front Behav Neurosci. 2016;10:189.
   PubMed Web of Science ®Google Scholar
• Grajales D, Ferreira V, Valverde AM. Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain. Cells. 2019 Nov;8(11):1336.
   PubMed Web of Science ®Google Scholar